Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human bone morphogenetic protein-2 + collagen type 1
- Development stage
- Unknown
- Lead developer
- Medtronic
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Local Injection
01
Overview
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a potent osteoinductive cytokine belonging to the transforming growth factor-beta (TGF-beta) superfamily. It acts by binding to specific receptors on the surface of mesenchymal stem cells, triggering a signaling cascade that promotes their differentiation into osteoblasts, thereby stimulating new bone formation. In the context of the Northern Orthopaedic Division study in Denmark, rhBMP-2 is combined with a bovine type 1 collagen carrier to serve as a substitute for autologous bone grafting in patients undergoing bone docking procedures following Ilizarov treatment for arthritis or degenerative bone disorders. This approach aims to reduce the morbidity associated with harvesting bone from the patient's own iliac crest while promoting effective ossification at the surgical site.
- Brand names
- InfuseInductOs
- Other names
- Bone Morphogenetic Protein 2recombinant human BMP-2
02
Targets
BMPR1ACOL1 (Collagen type I)BMPR2 (Bone morphogenetic protein receptor type II)BMPR1B
Beyond the preview
Go deeper on recombinant human bone morphogenetic protein-2 + collagen type 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human bone morphogenetic protein-2 + collagen type 1.